{"filing":{"accession_number":"0001213900-26-091783","cik":"0001514183","ticker":"SILO","company_name":"Silo Pharma, Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-18","primary_document":"ea0302618-8k_silo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026091783/ea0302618-8k_silo.htm"},"events":[{"id":28612,"run_id":26180,"accession_number":"0001213900-26-091783","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Silo Pharma entered into an asset purchase agreement with Parkview Consulting LLC to acquire software, technology, domain names, and related intellectual property in exchange for 165,000 shares of common stock. The transaction involves a related party and constitutes a material acquisition of assets.","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30611,"accession_number":"0001213900-26-091783","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Company entered into an asset purchase agreement with Parkview Consulting LLC to acquire software, technology, domain names, and related intellectual property in exchange for 165,000 shares of common stock. This constitutes a material acquisition of assets under Item 1.01, with consideration paid in equity. The transaction involves a related party (Corwin Yu serves on the Company's Cryptocurrency Advisory Board), and the lock-up restrictions on the issued shares indicate material significance to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:18:49.612424+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30612,"accession_number":"0001213900-26-091783","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities relying on Section 4(a)(2) of the Securities Act of 1933. The filing references \"the Shares\" sold to \"the Seller,\" indicating a private placement. For a small-cap pharmaceutical company like Silo Pharma, an unregistered equity issuance is material as it signals capital raising and potential shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:18:49.612424+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30611,"accession_number":"0001213900-26-091783","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Company entered into an asset purchase agreement with Parkview Consulting LLC to acquire software, technology, domain names, and related intellectual property in exchange for 165,000 shares of common stock. This constitutes a material acquisition of assets under Item 1.01, with consideration paid in equity. The transaction involves a related party (Corwin Yu serves on the Company's Cryptocurrency Advisory Board), and the lock-up restrictions on the issued shares indicate material significance to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:18:49.612424+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-08-19"},{"id":30612,"accession_number":"0001213900-26-091783","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities relying on Section 4(a)(2) of the Securities Act of 1933. The filing references \"the Shares\" sold to \"the Seller,\" indicating a private placement. For a small-cap pharmaceutical company like Silo Pharma, an unregistered equity issuance is material as it signals capital raising and potential shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:18:49.612424+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-08-19"}]}